WAVE LIFE SCIENCES LTD. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
WAVE LIFE SCIENCES LTD. (WVE) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $2.57 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $2.57M.
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $0.00.
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $0.00.
- WAVE LIFE SCIENCES LTD. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2016 was $1.07M.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.57M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | $2.60M 10-K · filed 2025-03-04 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2016-12-31 | $1.07M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |